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Association between use of systematic reviews and national 
policy recommendations on screening newborn babies for rare 
diseases: systematic review and meta-analysis
Sian Taylor-Phillips,1 Chris Stinton,1 Lavinia Ferrante di Ruffano,2 Farah Seedat,1 Aileen Clarke,1 
Jonathan J Deeks2,3
ABSTRACT
OBJECTIVE
To understand whether international differences 
in recommendations of whether to screen for rare 
diseases using the newborn blood spot test might 
in part be explained by use of systematic review 
methods.
DESIGN
Systematic review and meta-analysis.
DATA SOURCES
Website searches of 26 national screening 
organisations.
ELIGIBILITY CRITERIA FOR STUDY SELECTION
Journal articles, papers, legal documents, 
presentations, conference abstracts, or reports 
relating to a national recommendation on whether to 
screen for any condition using the newborn blood spot 
test, with no restrictions on date or language.
DATA EXTRACTION
Two reviewers independently assessed whether the 
recommendation for or against screening included 
systematic reviews, and data on test accuracy, 
benefits of early detection, and potential harms of 
overdiagnosis.
ANALYSIS
The odds of recommending screening according to 
the use of systematic review methods was estimated 
across conditions using meta-analysis.
RESULTS
93 reports were included that assessed 104 
conditions across 14 countries, totalling 276 
recommendations (units of analysis). Screening 
was favoured in 159 (58%) recommendations, 
not favoured in 98 (36%), and not recommended 
either way in 19 (7%). Only 60 (22%) of the 
recommendations included a systematic review. 
Use of a systematic review was associated with a 
reduced probability of screening being recommended 
(23/60 (38%) v 136/216 (63%), odds ratio 0.17, 
95% confidence interval 0.07 to 0.43). Of the 
recommendations, evidence for test accuracy, 
benefits of early detection, and overdiagnosis was 
not considered in 115 (42%), 83 (30%), and 211 
(76%), respectively.
CONCLUSIONS
Using systematic review methods is associated with a 
reduced probability of screening being recommended. 
Many national policy reviews of screening for rare 
conditions using the newborn blood spot test do not 
assess the evidence on the key benefits and harms of 
screening.
Introduction
Worldwide, the conditions screened for by the newborn 
blood spot test vary widely,1 2 with the number ranging 
from five to 60 on screening panels.3 4 Effective 
screening programmes can save lives, whereas 
ineffective programmes can do more harm than good—
for example, through overdiagnosis, the physical 
and psychological consequences of false positive 
test results, and opportunity costs for the healthcare 
system. It is not known whether the differences 
between countries result from genuine differences 
in disease prevalence or healthcare systems and 
priorities, or from differences in the evidence review 
process used to generate policy,5 in particular the use 
of systematic reviews.
Since Wilson and Jungner produced their World 
Health Organization report on screening in 1968, 
there has been a divergence in the methods used 
internationally for policy making about screening.6 
In Denmark, Finland, France, Germany, Italy, the 
Netherlands, Sweden, the UK, Australia, and New 
Zealand, national and regional organisations have 
updated and amended the Wilson and Jungner 
principles to fit their local context and to use their 
own versions to make policy recommendations and 
decisions about screening.7 In the United States, the 
US Preventative Services Task Force has developed an 
analytical framework that is adapted to the particular 
circumstances of each review.8 This includes three 
key elements that might determine the balance of 
benefits and harms from implementing screening for 
a condition: test accuracy for detecting the condition 
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WhAT IS AlReAdy knoWn on ThIS TopIC
Decisions about which conditions to screen for using the newborn blood spot 
test vary widely between countries, despite similar populations and healthcare 
systems
No systematic assessment has been done of the effect of evidence review 
methods used by different countries for decision making about screening using 
the newborn blood spot test
WhAT ThIS STudy AddS
Use of a systematic review of the evidence was associated with a reduced 
probability of screening being recommended 
42% of recommendations by national policy making organisations about whether 
to screen babies for diseases using the newborn blood spot test do not take 
account of the evidence on test accuracy, 36% do not review evidence about 
whether early treatment improves health outcomes, and 76% do not consider the 
evidence around potential harms of overdiagnosis
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of interest; the benefit of early detection, and 
therefore treatment after screening compared with 
later detection following symptoms; and the extent 
of overdiagnosis, one of the main harms of screening 
owing to the detection of disease that would never 
have caused symptoms within someone’s lifetime.
We analysed national policy making decisions about 
which conditions to screen for using the newborn blood 
spot test to determine whether systematic reviews were 
undertaken and if this was associated with the final 
recommendation of whether to implement screening. 
We also scored the extent to which each decision 
making process considered test accuracy, the benefit 
of early detection, and overdiagnosis, and investigated 
associations with the final decision.
Methods
Search
We searched the websites of national policy making 
organisations for all documentation related to 
the newborn blood spot test (see appendix 1 for 
organisations). A previous systematic review was 
used to identify these organisations.7 We asked a 
panel of international screening experts to identify 
any further documentation, and we searched website 
databases of WHO, the European Council, the 
European Commission, and the European Observer. 
From the included documentation, we extracted and 
synthesised data describing the process of reaching 
decisions for every condition considered for inclusion 
on the newborn blood spot screening panel, with no 
restrictions on date or language.
The initial search for this review was conducted on 
the websites of these national organisations on 18 
September 2015 using search terms for newborn blood 
spot screening and the conditions included by the 
American College of Medical Genetics (see appendix 2 
for full search terms). We emailed each organisation and 
country experts requesting any further documentation 
on newborn blood spot screening. If either referred us 
to associated but different organisations, we searched 
those websites using the same search terms between 
18 September 2015 and April 2016 (for example, in 
the US we searched the Preventative Task Force website 
and found that recommendations for the blood spot 
test are made by the Advisory Committee on Heritable 
Disorders in Newborns and Children. Similarly, after 
contacting the Ministry of Social Affairs and Health 
in Finland, we found that relevant reviews are on 
the Finnish HTA website). Overall, we searched the 
websites of 26 organisations.
Inclusion criteria
Two reviewers independently assessed each item 
against the inclusion criteria, with disagreements 
resolved by consensus. The inclusion criteria were:
Source of documents—only information from 
national policy making organisations was included. 
We excluded recommendations by state or regional 
organisations unless endorsed by a national policy 
making organisation, and recommendations by 
clinical societies or other groups unless they were 
explicitly used to underpin national policy decisions.
Type of document—we included all journal 
articles, papers, legal documents, presentations, 
conference abstracts, or reports from the website 
of the organisation and all those obtained through 
personal communication with policy makers, officials, 
and researchers in all included countries. We did not 
include patient information.
Language—there were no restrictions on language. 
For documents not in English we used automated 
translation software, with formal translation by native 
speakers if further clarity was needed.
Subject of documents—we included material on 
whether to start or stop screening or material that 
evaluated the effectiveness of current or proposed 
screening programmes for any condition using the 
newborn blood spot test. If we also found reviews of 
conditions for that country, we included documents 
describing standards for national evidence review 
processes for screening.
Method of reaching recommendation—we included 
recommendations produced using all methods, 
including evidence from systematic reviews, 
expert panels, or any approach that resulted in a 
recommendation or decision or described why or how 
a decision was made.
Data extraction
Two reviewers independently extracted data, with 
disagreements resolved by consensus and involvement 
of a third reviewer if necessary (see appendix 3 for 
data extraction sheet). Data extraction was carried out 
in two steps. Firstly, we recorded whether any of the 
review documentation included a systematic review. 
The criteria for defining a systematic review were 
inclusive; we required either two parts of the search 
strategy (for example, search terms, databases, dates) 
to be described or any details of systematic evidence 
selection after a search (for example, inclusion criteria, 
PRISMA flow chart) to be described (table 1). We 
were also inclusive about the question posed by the 
systematic review, which could address any aspect 
of the evidence relating to whether or not to screen 
for a condition, including benefits of early detection 
through screening, disease prevalence, test accuracy, 
effects of false positive test results, overdiagnosis or 
any other harm, and clinical course of the condition.
Criteria for defining a systematic review: A: describes 
two parts of the search strategy (eg, search terms, 
databases, dates), or B: describes any details of 
systematic evidence selection after a search (eg, inclusion 
or exclusion criteria, numbers at abstract and full text 
sift, PRISMA flow diagram). Each country was defined as 
having undertaken a systematic review for each condition 
if either criterion A or B, or both, were met. 
The review topic could be about any aspect of 
screening for the disease under consideration (eg, 
benefits of early detection through screening, disease 
prevalence, test accuracy, effects of false positive test 
results, overdiagnosis or any other harm, clinical course).
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Secondly, we assessed three key elements 
characterising the main benefits and harms of 
screening: test accuracy, benefits of early detection 
through screening, and overdiagnosis. These 
characteristics were selected on the basis of our review 
of published frameworks for test evaluation9-12 to 
identify all mechanisms recognised to affect patient 
health as a result of undergoing testing or taking part 
in a screening programme.
Table 2 details the scoring system for the assessment 
of evidence related to the three key elements. We 
measured whether and how the evidence was assessed; 
not what the evidence showed about that particular 
condition. A score of zero means that the element was 
not mentioned in the documentation, with increasing 
scores up to a score of 5 indicating greater and more 
systematic use of evidence and increasing assessment of 
internal and external validity. A score of ≥3 for any of the 
three key elements indicates that a systematic review 
was used for that recommendation. In some cases a 
systematic review was used and recorded as such but 
the review did not cover test accuracy, benefit of early 
detection, or overdiagnosis. In such cases, the evidence 
would score <3 for these three key elements in the 
secondary analyses but was still coded as a systematic 
review in the primary analysis (meta-analysis).
Test accuracy determines how many people are 
detected early with true positive test results and how 
many are potentially harmed by false positive results. 
The scoring system refers to whether there is an accurate 
test, which can include any test accuracy metrics such 
as sensitivity, specificity, and positive or negative 
predictive value. Consideration of the existence of a test 
is a necessary prerequisite but does not form part of the 
scoring system. The benefit of early detection leading 
to early treatment is the primary mechanism through 
which screening provides benefit. The scoring system 
refers specifically to the benefit of early treatment, not 
whether there is an effective treatment, which is also 
a prerequisite. Overdiagnosis in this context is defined 
as detection of disease at screening that would never 
have produced symptoms within someone’s lifetime. 
We were inclusive in the language used to describe 
overdiagnosis, including asymptomatic phenotypes, 
penetrance, and any description of people remaining 
symptom-free to adulthood.
Statistical analysis
Cohen’s κ was used to calculate inter-reviewer 
reliability for judgments of whether a systematic 
review was used, scores for the test accuracy, 
benefits of early detection, and overdiagnosis, and 
whether screening was recommended, with linear 
weighting when more than two categories existed, 
and interpretation according to Landis and Koch.25 
We report proportions of included decisions that 
used systematic review methods; the methods used 
to assess test accuracy, benefit of early detection, and 
overdiagnosis (graphs show distribution of scores); 
and the final recommendation tabulated by country. 
To determine whether the patterns observed were 
purely historical we repeated the analysis including 
only policies since 2012.
We computed the odds ratio for recommending 
screening for each condition if a systematic review 
was used compared with recommending screening 
if a systematic review was not used. To get an 
overall estimate of the impact of using systematic 
reviews on policy formation of recommendations, we 
meta-analysed odds ratios across conditions. This 
stratified approach removes the confounding effect 
of clinical condition. Only conditions where there 
were discrepancies in recommendations (ie, at least 
one recommendation for and one recommendation 
against screening) and in methods (ie, at least one 
recommendation with systematic review evidence and 
one without) could contribute to this comparison and 
were included in the meta-analysis. We calculated an 
overall effect estimate using Mantel-Haenszel fixed 
effects meta-analysis with a 0.1 zero cell correction.26 27 
The analyses were repeated with no and other values 
of zero cell correction (0.5, 0.01, 0.001), using the 
DerSimonian and Laird random effects method 
with zero cell correction 0.5, and the Peto method.27 
Table 1 | Criteria for defining whether each country undertook a systematic review for each condition, with examples
Country Condition
Systematic  
review used Rationale for classification
Nether-
lands
Carnitine acylcarnitine  
translocase deficiency
No No methods given, but likely expert consensus. Section 1.3.4 states “the committee believes that this disease 
should be classified in Category 179” (category 1 refers to conditions that the committee considered as 
 qualifying for inclusion in the newborn screening programme)
Denmark Multiple carboxylase  
deficiency
No Section 4 states: “[we] assessed the conditions selected for additional analysis, which was based on a review of 
original literature including treatment options, screening potential and experience.”82 No further details of the 
review process were provided
Canada Phenylketonuria Yes Section 17 outlined the review methods, and included: source searched (Medlline only), search term 
( phenylketonuria), and date limit.95 Meets criterion for describing two parts of the search strategy
UK Long chain 3-hydroxyacyl- 
CoA dehydrogenase  
deficiency
Yes “Chapter 5 provides a methodology for the systematic review.” This included the search strategy, resources 
searched (electronic databases and reference lists of identified articles), search terms, date limit, language 
 restrictions, and number of reviewers; and the inclusion and exclusion criteria.22 Meets both criteria for defin-
ing a systematic review because at least two parts of the search strategy and inclusion criteria were described
Criteria for defining a systematic review: A: describes two parts of the search strategy (eg, search terms, databases, dates), or B: describes any details of systematic evidence selection after a 
search (eg, inclusion or exclusion criteria, numbers at abstract and full text sift, PRISMA flow diagram). Each country was defined as having undertaken a systematic review for each condition if 
either criterion A or B, or both, were met. 
The review topic could be about any aspect of screening for the disease under consideration (eg, benefits of early detection through screening, disease prevalence, test accuracy, effects of false 
positive test results, overdiagnosis or any other harm, clinical course).
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Table 2 | Scoring system for assessment of evidence for test accuracy, benefit of early treatment, and overdiagnosis
Score* Definition
Examples
Test accuracy Benefit of earlier treatment Overdiagnosis
0 Not considered 
at all
USA, American College of Medical 
Genetics recommendation to screen 
for 3-hydroxy-3-methyglutaric 
aciduria “Screening test: MSMS 
[tandem mass spectrometry]. 
 Reported in 1990 [references given]” 
(the references provided refer to 
how to undertake testing using MS/
MS, but provide no details on test 
accuracy13)
USA, argininemia: “Treatment is expected to 
reduce neurological dysfunction [references 
given].” References refer to treatment effective-
ness not benefit of earlier treatment (after screen 
detection) over later treatment (after symptomatic 
detection)13
Overdiagnosis not mentioned using any form of 
wording, including asymptomatic phenotypes, 
 penetrance, and any description of people 
 remaining symptom-free to adulthood
1 Considered in some 
way (mentioned 
in at least one 
 document once)
Netherlands, tyrosinemia type I: “It is 
possible to make the test specific for 
tyrosinemia type I and greatly reduce 
the number of false-positives by also 
measuring the amount of succinyl 
acetone in the blood specimen [no 
reference given]”14
USA, congenital hypothyroidism: “Some evidence 
that early intervention optimizes individual out-
comes [no reference given]”13
USA, 3-methylcrotonyl-CoA carboxylase deficiency: 
“since newborn screening with MS/MS [tandem 
mass spectrometry] began, many individuals 
have been identified with the analytes associated 
with the condition but without apparent clinical 
 manifestations [no reference given]”13
2 Measured in some 
way (at least one 
study or source 
cited, and for test 
accuracy at least 
some numerical 
estimate given) or 
acknowledged that 
data do not exist yet
New Zealand, economic model 
of screening for severe combined 
immunodeficiency: table 4 model 
assumptions “test sensitivity 0.999, 
test specificity 0.996 [reference 
given]”15
New Zealand, nomination form for removal of 
3-methylcrotonyl-CoA carboxylase deficiency 
3MCC from the screening panel: “RCTs [ran-
domised controlled trials] are not possible in new-
born metabolic screening due to the low incidence 
of the disorders, and the time period required to 
generate a statistically significant number of cases 
in the screening arm versus the control arm. Case 
studies suggest screening is not effective in reduc-
ing mortality or morbidity [reference given]”16
Denmark, biotidinase deficiency: “It is unclear 
whether asymptomatic children with partial biotini-
dase deficiency need treatment [references given]”17
3 Investigated using 
systematic methods 
of collecting 
evidence (score 
if detail two parts 
of search strategy 
or any details of 
evidence selection 
methods)
Spain, findings of a systematic 
review of biotidinase: “Therefore 
sensitivity and specificity of the test 
is estimated at 100% and 99.994%, 
respectively. These results are very 
similar to those presented in Kwon & 
Farrel, 2000 [reference given]”18
Canada, systematic review of cystic fibrosis (CF): 
“Before any screening program is implemented 
there should be good evidence that people iden-
tified in the presymptomatic phase do better than 
those in whom a diagnosis is made because of 
symptoms . . . Several cohort studies of screened 
and unscreened subjects have suggested that 
early diagnosis does make a difference. In one 
study in the Netherlands, 88% of screened chil-
dren but only 60% of unscreened children were 
still alive at age 11 years. In an earlier study by 
the same group, screened children were found to 
have better clinical scores at age 8 years than did 
unscreened children with CF, but the differences 
in chest x-ray films, heights and weights were not 
statistically significant [reference given]”19
France, systematic review of medium-chain acyl-CoA 
dehydrogenase deficiency: “Screening results in the 
United States, Germany and Australia have revealed 
the presence of a relatively frequent mutation 
which was not found in patients exhibiting clinical 
symptoms [references given]. Studies in vitro have 
demonstrated that this mutation is associated with 
a reduction in the enzymatic activity which may not 
necessarily have any clinical significance [reference 
given]”20
4 Systematic 
review and mention 
external validity 
(generalisability to 
local context) or in-
ternal validity (bias 
or confounding) of 
 evidence or hierar-
chy of evidence
Spain, systematic review of classic 
galactosemia: “sensitivity of 100% 
and a specificity of 99.9% in all 
programs, although these data 
should be interpreted with caution 
in the absence of studies to conduct 
a verification of negative cases 
[reference given]”21
UK, systematic review of maple syrup urine dis-
ease: “Other authors provide shorter case-history 
approaches to identification of improved clinical 
outcomes from screen detected patients. These 
include [references given] all of whom compare 
small numbers of pre-symptomatically detected 
versus clinically detected cases but without 
 construction of comparative cohorts”22
USA, systematic review of Krabbe disease: “Of the 
seven high-risk cases detected in New York (Table 
6), two were considered EIKD [early infantile Krabbe 
disease] and referred for HSCT [hematopoietic stem 
cell transplant] because of their GALC [galacto-
sylceramidase] genotypes and the early signs of 
neurologic disease. One of these patients was 
homozygous for the 30-kb deletion mutation, while 
the other patient was heterozygous for the 30-kb 
deletion and a novel mutation. Dr. Wenger reports 
that the five remaining children who screened high 
risk had genotypes considered to put them at a low 
risk for early onset of disease. Dr. Caggana and Dr. 
Orsini state that two of these children were lost to 
follow-up and three are being followed on a quar-
terly basis by a neurologist. One of these children 
is known to be asymptomatic and the other two are 
assumed to be asymptomatic as Dr. Caggana and 
Dr. Orsini have not heard otherwise23
5 Systematic review 
and assessed 
using formal quality 
assessment
No examples found Belgium, systematic review of CF provides full 
quality assessment of the studies in an appendix, 
with summary: “The studies performed to support 
CF NBS [newborn screening] is not as strong as 
one might expect, knowing that there are still two 
large randomized trials (RCTs) [that] were designed 
to evaluate CF NBS. The design of the UK RCT 
(1985-1989) was substandard and this study 
was therefore not retained in a recent Cochrane 
review. The Wisconsin RCT (1985-1995) did have 
a proper design and demonstrated a significant 
advantage of CF NBS in the field of nutrition and 
growth (weight and length). However, in [relation 
to] lung function, no benefit from CF NBS could be 
demonstrated”24
No examples found
*Scores are cumulative—for example, a score of 3 can only be achieved if meeting all criteria to score 1, 2, and 3.
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We tested for heterogeneity using Cochran’s Q and 
described its magnitude using the I2 statistic. All 
analyses used Stata version 13.
Spearman correlation was used to univariately 
assess the relation between policy recommendations 
and the rigor of methods used to assess test accuracy, 
the benefits of early detection and treatment, and 
the risks of overdiagnosis (only systematic reviews 
of conditions for which there were recommendations 
both for and against screening were included in this 
analysis).
Patient involvement
No patients were involved in setting the research 
question or the outcome measures, nor were 
they involved in developing plans for design or 
implementation of the study. No patients were asked 
to advise on interpretation or writing up of results. We 
will work with patients and members of the public to 
help disseminate findings to appropriate audiences.
Results
Description of evidence
We identified 134 policy documents (fig 1), 108 of 
which were from screening organisation websites and 
26 referred from experts. Overall, 41 documents were 
excluded. Reasons for exclusion were: description 
of current screening practice, policy, or laws; list of 
conditions included or considered for inclusion in 
programme; document stating decision to change 
programme; document not from national organisation; 
duplication of included information; patient 
information; description of organisation or study; 
no investigation of an included condition; contracts; 
and not newborn blood spot test (see appendix 4 for 
references of exclusions with reasons). After exclusions, 
93 reports remained.13-108 Two covered Australia and 
New Zealand together,30 33 two were from Australia,61 87 
four from Belgium,24 68 69 105 three from Canada,19 37 95 
two from Denmark,17 82 three from Finland,31 59 85 
eight from France,20 34 35 71 72 99 100 104 three from 
Germany,106-108 one from Italy,102 four from Japan,53 66-88 
four from the Netherlands,14 79-81 two from New 
Zealand,15 16 24 from Spain,18 21 32 39-51 76-78 83 86 89-91 
eight from the United Kingdom,22 36 38 52 58 73 84 94 and 23 
from the USA.13 23 28 29 54-57 60 62-65 70 74 75 92 93 96-98 101 103
Review methods used
Overall, the 93 reports included 104 conditions from 14 
countries, giving a total of 276 recommendations (units 
of analysis). Cohen’s κ for inter-reviewer reliability was 
0.91 (near perfect) for whether a systematic review was 
used, 0.73 (substantial) for test accuracy score, 0.47 
(moderate) for benefit of early detection score, 0.62 
(substantial) for overdiagnosis score, and 0.97 (near 
perfect) for the final recommendation of each review.
Of the 276 recommendations, 159 (58%) were in 
favour of screening, 98 (36%) were against screening, 
and no suggestion was made either way in 19 (7%). 
Sixty (22%) of the recommendations included evidence 
from a systematic review. Of the recommendations, 
evidence for test accuracy, benefits of early detection, 
and overdiagnosis was not considered in 115 (42%), 
83 (30%), and 211 (76%), respectively. Of the 60 
recommendations that employed systematic review 
methods, 21 systematic reviews covered test accuracy, 
benefits of early detection, and overdiagnosis. Figure 2 
shows the full distribution of scores. Similar patterns 
are observed if only the most recent 154 reviews 
(from 2012 onwards) are included (see supplemental 
figure 1). Table 3 shows a full breakdown by country.
Association between evidence review methods and 
recommendations
Of the 60 decisions that included a systematic 
review, 23 (38%) recommended screening, 29 (48%) 
recommended not to screen, and eight (13%) made 
no recommendation either way. The corresponding 
results for the 216 decisions not based on evidence 
Additional records identied
through experts (n=26)
Records identied
through websites (n=108)
Studies included in synthesis (n=93):
  Australia and New Zealand (n=2)
  Australia (n=2)
  Belgium (n=4)
  Canada (n=3)
Denmark (n=2)
Finland (n=3)
France (n=8)
Germany (n=3)
Italy (n=1)
Japan (n=4)
Netherlands (n=4)
New Zealand (n=2)
Spain (n=24)
UK (n=8)
USA (n=23)
Full text records assessed for eligibility (n=134)
Full text records excluded (see appendix 4) (n=41):
  Description of current screening practice, policy, or laws (n=14)
  List of conditions included or considered for inclusion in programme (n=6)
  Document stating decision to change programme (n=6)
  Document not from national organisation (n=4)
  Duplication of included information (n=4)
  Patient information (n=2)
  Description of organisation or study (n=2)
  No investigation of an included condition (n=1)
  Contract (n=1)
  Not newborn blood spot test (n=1)
Fig 1 | Flow of documents through study. One paper was included from Italy, but no 
national decisions in the analysis, because one paper that will be used in part to 
underpin the national decisions has been published, but the national review process is 
incomplete and recommendations are yet to be made
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Fig 2 | Distribution of scores for evaluating test accuracy, 
benefits of early versus late detection and treatment, 
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elements were not considered at all, and 5 indicates 
that they were assessed using a systematic review with 
formal quality appraisal
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from a systematic review were 136 (63%), 69 (32%), 
and 11 (5%).
The meta-analysis included 24 conditions, each 
with between two and eight reviews, with 104 reviews 
in total. The odds of making a decision to recommend 
screening was lower when a systematic review was used 
than when no systematic review was used (odds ratio 
0.17, 95% confidence interval 0.07 to 0.43, P<0.001; fig 
3). Owing to the small sample sizes, little heterogeneity 
existed between conditions (χ2=12.45 (df=23), P=0.96), 
with none of the total variance due to variability between 
conditions (I2=0%). Sensitivity analyses using different 
zero cell corrections and meta-analysis methods did 
not alter the results and were all highly significant 
(P<0.001), although increasing the zero cell correction 
did slightly reduce the effect size (see appendix 2).
Review scores for benefits of early detection and 
overdiagnosis were not statistically significantly 
correlated with the recommendation of the review, 
although there was an association between greater 
consideration of test accuracy in the review and 
a recommendation against screening (table 4). 
Table 3 | Review methods and decisions for each country
Country
Proportion of decisions, % (No/total No) Review scores (No*)
Recommended  
screening
Used systematic  
review
Test accuracy Early detection Overdiagnosis
0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5
Australia 100 (1/1) 0 (0/1) 0 0 1 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0
Belgium 14 (1/7) 14 (1/7) 0 1 5 1 0 0 0 3 3 0 0 1 4 2 0 1 0 0
Canada 83 (5/6) 67 (4/6) 2 0 0 3 1 0 3 0 1 1 1 0 5 0 1 0 0 0
Denmark 60 (21/35) 0 (0/35) 4 3 28 0 0 0 8 16 11 0 0 0 25 9 1 0 0 0
Finland 0 (0/7) 100 (7/7) 1 4 1 1 0 0 0 7 0 0 0 0 6 1 0 0 0 0
France 33 (1/3) 100 (3/3) 0 0 2 1 0 0 0 0 0 1 2 0 0 2 0 1 0 0
Germany 100 (1/1) 100 (1/1) 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 1 0 0
Japan 81 (25/31) 0 (0/31) 27 2 2 0 0 0 30 0 1 0 0 0 30 1 0 0 0 0
Netherlands 55 (29/53) 0 (0/53) 21 13 19 0 0 0 18 23 12 0 0 0 48 3 2 0 0 0
New Zealand 13 (1/8) 75 (6/8) 0 5 2 0 0 0 5 1 2 0 0 0 7 0 1 0 0 0
Spain 41 (11/27) 100 (27/27) 6 0 0 20 1 0 3 0 0 22 2 0 10 5 0 12 0 0
UK 75 (6/8) 63 (5/8) 0 0 3 4 1 0 0 2 2 1 3 0 2 0 1 5 0 0
USA 64 (57/89) 7 (6/89) 53 15 15 0 6 0 16 19 49 0 5 0 74 3 10 0 2 0
*Number of included recommendations with each evidence score.
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Fig 3 | Forest plot of the odds of recommending screening in decisions that included compared with did not include evidence from a systematic 
review. Overall effect estimate from fixed effects meta-analysis with a 0.1 zero cell correction
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Confidence intervals were wide, narrowly excluding 
zero for test accuracy and just overlapping zero for 
overdiagnosis score.
discussion
We assessed whether use of a systematic review affects 
national decisions on whether to screen for a range of 
conditions using the newborn blood spot test. After 
full text review, we included 93 reports assessing a 
total of 104 conditions across 14 countries, with 276 
recommendations. Only 22% of the recommendations 
were based on evidence from a systematic review. The 
odds of a decision in favour of screening were lower 
when a systematic review was used as part of the 
policy decision (0.17, 95% confidence interval 0.07 
to 0.43). The evidence on accuracy of the test was not 
evaluated in 42% of recommendations. Similarly, the 
evidence around the benefits of early detection and the 
potential harm of overdiagnosis were not evaluated in 
30% and 76% of reviews, respectively. These elements 
were actually not mentioned in the review documents, 
which suggests either lack of evidence review or lack 
of consideration. For each review, the more thoroughly 
test accuracy was considered the lower was the 
probability that screening would be recommended. 
A weak association was found in the same direction 
for thoroughness of assessment between both early 
treatment benefits and overdiagnosis and screening 
recommendations. However, power was too limited 
to assess these associations, owing to the low scores 
creating a floor effect.
Strengths and limitations of this study
The strengths of this study include the large number of 
documents extracted using systematic methods, with 
no restrictions on date, language, or country, and the 
use of meta-analytical methods to determine whether 
there was a consistent effect across different conditions 
thus accounting for confounding by condition. Also we 
used automated translation software, which enabled 
broader inclusion criteria, although errors might have 
occurred in translation. To mitigate this risk, we used 
formal translation for documents or parts of documents 
where the automated translation was unclear to 
reviewers. In addition, the review of grey literature 
documenting national policy decisions is challenging 
in itself, particularly on reproducibility since websites 
change over time. We also contacted every organisation 
for further documents, but it is possible that more 
systematic reviews were used than were published or 
referenced by the national websites of policy makers or 
identified through personal communication.
Although we found an association between use of 
systematic reviews and whether or not a screening 
programme was recommended, the decision on 
whether to undertake a systematic review might have 
been driven by country level factors, as four of the 14 
included countries always used a systematic review 
and four never did. Thus it might be possible that 
use of systematic review methods acted as a proxy 
for unmeasured country level confounders, so only 
tentative conclusions can be drawn.
Comparison with other studies
Previous research has highlighted an underuse of 
systematic reviews in developing policy guidance for 
screening programmes. A 2006 study reported that 
systematic reviews were rarely used in production 
of WHO guidance, a discovery that initiated a 
major research effort to incorporate greater use 
Table 4 | Number of reviews recommending screening and no screening by scores for test accuracy, benefit of early 
detection, and overdiagnosis
Scores
Recommendation Proportion recommend  
screening (%)
Spearman correlation  
coefficient* (95% CI) P valueScreening No screening
Test accuracy:
 0 41 14 75
−0.17 (−0.33 to −0.01) 0.04
 1 10 8 56
 2 27 16 63
 3 10 11 48
 4 2 1 67
 5 0 0
Benefits of early detec-
tion:
 0 27 17 61
−0.06 (−0.22 to 0.11) 0.51
 1 23 11 68
 2 30 7 81
 3 5 13 28
 4 4 2 67
 5 1 0 100
Overdiagnosis:
 0 71 34 68
−0.13 (−0.29 to 0.03) 0.12
 1 5 5 50
 2 7 3 70
 3 7 8 47
 4 0 0
 5 0 0
*Correlation is between scores and whether screening was recommended (only includes reviews of conditions where at least one review recommended 
screening and one did not).
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of systematic reviews.109 Although the research 
literature concerning measurement of overdiagnosis 
is extensive, our study systematically investigated 
whether consideration of potential overdiagnosis is 
incorporated into national screening policy decision 
making. Our main finding, however, was that policy 
reports that did not utilise systematic review methods 
were more likely to recommend screening, suggesting 
that rigorous appraisal exposes the absence or 
unreliability of available evidence. Indeed, several 
studies have shown differences between expert 
opinion and research evidence. One study observed 
that professional recommendations on treatments for 
acute myocardial infarction communicated through 
review articles or textbooks often contradicted the 
best evidence from meta-analysis of trials available 
at the time of publication.110 An opinion article 
argued that experts are more likely to overestimate 
the effectiveness of interventions based on their own 
clinical experiences.111 In fact a systematic review 
showed that clinicians overestimate the benefits of 
screening and underestimate the harms.112 We consider 
that quality appraisal in systematic reviewing serves 
as a mechanism to highlight bias in research studies 
(often biased away from the null). This might explain 
why expert policy making groups that use systematic 
reviews are less likely to recommend screening.
Policy implications
This study showed that many national policy decisions 
about whether to screen for conditions using the 
newborn blood spot test are being made without 
systematically reviewing the evidence. One reason for 
this absence is likely to lay in the absence of evidence 
from randomised controlled trials, which is unavailable 
for most conditions included in the newborn blood 
spot owing to their rarity. Indeed, although many 
countries have developed robust systems for reviewing 
new screening programmes, we found that they are 
often not applied when assessing whether to screen for 
additional rare diseases using the newborn blood spot 
test. Yet it remains essential to make evidence based 
policy decisions because once screening programmes 
are started they are difficult to stop.12 When trial 
evidence is not available, a review of whether to screen 
for each condition should consider the evidence for 
each pathway to patient benefit and harm resulting 
from introducing a screening test, in particular: the 
test’s ability to discern true disease, any resulting 
potential for patient harm from overdiagnosis, and 
the benefits of early detection. Although many reviews 
considered whether subsequent diagnostic tests and 
treatments were available to manage screened patients, 
most did not consider evidence for the screening test’s 
accuracy, nor whether earlier detection and treatment 
after screening were beneficial to patients compared 
with later detection of symptoms and treatment. These 
three elements are not an exhaustive list of benefits and 
harms (for example, we did not examine the effect of 
screening results to other family members); however, 
there is broad agreement that they are key indicators 
of effectiveness.10 11 We recommend that whenever 
possible a systematic review of the literature should 
be undertaken as part of policy decisions on whether 
to commence screening. Full systematic reviews that 
assess each key element of a screening programme 
can be expensive and time consuming—particularly 
in the absence of trial evidence, and we propose more 
international collaboration to undertake such reviews. 
Although the health systems, prevalence, culture, 
and willingness to pay thresholds might differ by 
country, the evidence about test accuracy, benefits of 
early detection, and overdiagnosis are international 
bodies of evidence, and collating them will be the 
same regardless of country. Only concerns about 
applicability will differ.
Conclusions
Further research is required to understand why policy 
makers do not employ systematic review methods 
in their evaluations of evidence. Possible reasons 
include costs, time, and knowledge and beliefs about 
systematic reviews.113 Undertaking international 
reviews for conditions across several countries would 
reduce overall costs. These reviews could be adapted 
to local populations and prevalence and improve 
rigour while reducing discrepancies in screening 
internationally.
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